Clayton Lau, MD, on How COVID-19 Has and Will Continue to Impact Cancer Care

Article

The chief of urologic oncology at City of Hope spoke about how the COVID-19 pandemic has altered the way he cares for patients with cancer as well as how he believes it will continue to impact cancer prevention, detection, and treatment moving forward.

Numerous studies have been published recently highlighting the impact that the coronavirus disease 2019 (COVID-19) pandemic has had on cancer prevention, detection, and treatment.

Though it is not yet known what the full impact of the pandemic will be, these studies emphasize concerns that delays in care could result in a rise of late-stage diagnoses and cancer deaths in the coming years.

In an interview with CancerNetwork®, Clayton Lau, MD, chief of urologic oncology at City of Hope, discussed how COVID-19 has affected his ability to treat patients with cancer as well as how he believes the pandemic will continue to shape cancer care.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.

Recent Videos
Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, described the excitement of seeing novel molecules like antibody drug conjugates become more prominent.
Ronald Bleday, MD, credits a chronic pain clinic for consulting patients who may be at a greater risk for prolonged opioid use following surgery.
Ronald Bleday, MD, stated that before standardizing a stepwise approach to treating surgical pain, providers might have overtreated patients with opioids.
Conducting trials safely within a community setting lies at the heart of a successful collaboration between Northwell Health and START.
The expertise of START's network may streamline the availability of clinical trial enrollment and novel treatment options among patients with cancer.
A new START center in New York may give patients with advanced malignancies an opportunity to access novel therapies in the community setting.
START is the largest early phase oncology network in the community-based setting, according to Geraldine O’Sullivan Coyne, MD, MRCPI, PhD.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
Related Content
Cryotherapy Device Improves Oral Mucositis Outcomes After Chemotherapy Treatment

Cryotherapy Device Improves Oral Mucositis Outcomes After Chemotherapy Treatment

Ariana Pelosci
August 25th 2025
Article

The Chemo Mouthpiece had favorable outcomes when used during and after treatment with chemotherapy among a range of patients with various types of cancer.

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, discusses how the START center may expand access to novel therapies for patients who reside in a community.

START Center Aims to Bring New Cancer Treatments, Trials to The Community

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD
August 25th 2025
Podcast

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, discusses how the START center may expand access to novel therapies for patients who reside in a community.

The EC decision is based on phase 3 DeFi trial results, in which nirogacestat met the primary end point of PFS in patients with progressing desmoid tumors.

Nirogacestat Receives European Approval for Treatment of Desmoid Tumors

Roman Fabbricatore
August 18th 2025
Article

The EC decision is based on phase 3 DeFi trial results, in which nirogacestat met the primary end point of PFS in patients with progressing desmoid tumors.

Best Practices for the Medical Oncology Boards

Best Practices for the Medical Oncology Boards

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD
July 7th 2025
Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.

Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With Cancer

Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With Cancer

Viviana Cortiana, MS4;Maduri Balasubramanian, MD;Jade Gambill, BS;Diksha Mahendru, MD;Kennedy Itodo, MD;Chandler H. Park, MD, MS, FACP;Yan Leyfman, MD
August 15th 2025
Article

Immunocompromised individuals face ongoing COVID-19 risks despite vaccination, highlighting the need for tailored public health strategies and innovative therapies.

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, shares how a new position presents a “good opportunity” to improve community-based clinical trial access.

New Unit Aims to Expand Trial and Therapy Options in The Community Setting

Russ Conroy
August 14th 2025
Article

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, shares how a new position presents a “good opportunity” to improve community-based clinical trial access.